Univar Inc. (NYSE:UNVR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm presently has a $24.00 target price on the stock. Zacks Investment Research’s target price would indicate a potential upside of 11.68% from the company’s current price.
According to Zacks, “Univar Inc. is a distributor of chemicals and innovative services. The Company offers solvents, resins, pigments, acids, bases, surfactants, glycols, inorganic compounds and alcohols. It also offers transportation and warehousing infrastructure, chemicals and hazardous materials handling services. The Company’s operating geographical segments include Univar USA, Univar Canada, Univar Europe and the Middle East as well as Rest of World. It serves coatings and adhesives, food, oil and gas, personal care and pharmaceutical industries. Univar Inc. is headquartered in Downers Grove, Illinois. “
Several other equities analysts also recently weighed in on the stock. Jefferies Group initiated coverage on shares of Univar in a research note on Friday, September 9th. They issued a “buy” rating and a $26.00 target price for the company. Barclays PLC downgraded shares of Univar from an “overweight” rating to an “equal weight” rating and set a $20.00 target price for the company. in a research note on Friday, June 24th. They noted that the move was a valuation call. Bank of America Corp. set a $22.00 price objective on shares of Univar and gave the company a “buy” rating in a research report on Thursday, August 11th. Finally, Wells Fargo & Co. restated a “hold” rating on shares of Univar in a research report on Sunday, September 4th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $22.50.
Univar (NYSE:UNVR) opened at 21.49 on Wednesday. The firm has a 50-day moving average of $20.90 and a 200 day moving average of $19.15. Univar has a 12 month low of $10.65 and a 12 month high of $22.76. The firm has a market capitalization of $2.96 billion, a PE ratio of 46.92 and a beta of 1.24.
Univar (NYSE:UNVR) last posted its earnings results on Tuesday, August 9th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.13. The firm earned $2.30 billion during the quarter, compared to the consensus estimate of $2.23 billion. Univar had a net margin of 0.75% and a return on equity of 7.73%. The company’s revenue was down 9.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.12) earnings per share. Equities research analysts forecast that Univar will post $0.72 earnings per share for the current year.
In other Univar news, major shareholder Nv Univar sold 20,527,358 shares of Univar stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $19.00, for a total transaction of $390,019,802.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher D. Pappas bought 5,000 shares of the company’s stock in a transaction on Thursday, August 11th. The shares were bought at an average price of $19.26 per share, with a total value of $96,300.00. Following the completion of the transaction, the director now owns 50,088 shares of the company’s stock, valued at $964,694.88. The disclosure for this purchase can be found here. Company insiders own 2.49% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. raised its stake in shares of Univar by 1.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 120,574 shares of the company’s stock worth $2,281,000 after buying an additional 1,350 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of Univar by 16.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 31,254 shares of the company’s stock worth $591,000 after buying an additional 4,329 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in shares of Univar during the second quarter worth $917,000. A.R.T. Advisors LLC raised its stake in shares of Univar by 75.5% in the second quarter. A.R.T. Advisors LLC now owns 78,166 shares of the company’s stock worth $1,478,000 after buying an additional 33,616 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Univar by 56.0% in the second quarter. Barclays PLC now owns 67,100 shares of the company’s stock worth $1,269,000 after buying an additional 24,100 shares during the last quarter. Institutional investors and hedge funds own 80.18% of the company’s stock.
Univar Inc is a distributor of commodity and specialty chemicals. The Company’s segments include Univar USA (USA); Univar Canada (Canada); Univar Europe, the Middle East and Africa (EMEA), and Rest of World. The Rest of World segment includes developing businesses in Latin America, including Brazil and Mexico, and the Asia-Pacific region.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Univar Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Univar Inc. and related companies with MarketBeat.com's FREE daily email newsletter.